Important Steps Forward Taken by Vir Biotechnology and Separately by Compugen

Vir Biotechnology
Vir Biotechnology (VIR) announced the dosing of the first patient in the Phase 2 MARCH (Monoclonal Antibody siRNA Combination against Hepatitis B) trial to evaluate VIR-2218 together with VIR-3434 for the treatment of patients with chronic hepatitis B virus (HBV) infection – a combination designed to achieve a functional cure.

VIR-2218 is an investigational . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.